US 11,951,150 B2
Compositions and methods for preventing and reducing inflammation and treating disorders associated with inflammation
Jack J. Hawiger, Nashville, TN (US); Ruth Ann Veach, Brentwood, TN (US); Yan Liu, Nashville, TN (US); Huan Qiao, Nashville, TN (US); and Lukasz S. Wylezinski, Nashville, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Jun. 7, 2021, as Appl. No. 17/341,379.
Application 17/341,379 is a division of application No. 16/448,960, filed on Jun. 21, 2019, granted, now 11,026,992.
Application 16/448,960 is a continuation of application No. 15/055,915, filed on Feb. 29, 2016, granted, now 10,342,847, issued on Jul. 9, 2019.
Claims priority of provisional application 62/121,685, filed on Feb. 27, 2015.
Prior Publication US 2022/0105148 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/10 (2006.01); A61K 38/18 (2006.01); C07K 7/00 (2006.01)
CPC A61K 38/10 (2013.01) [A61K 38/1825 (2013.01); C07K 7/00 (2013.01); C07K 2319/00 (2013.01)] 6 Claims
 
1. A method of treating BCL10-mediated inflammation in a mammalian subject comprising administering to the mammalian subject a composition comprising a pharmaceutically acceptable carrier and a cell-penetrating full-length caspase and receptor interacting protein adaptor with death domain (CP-CRADD), CP-CRADD that lacks its death domain or CP-CRADD that lacks its caspase recruitment domain (CARD) and further comprising, a membrane-translocating motif (MTM) having the sequence AAVLLPVLLAAP (SEQ ID NO: 1), AAVALLPAVLLALLAP (SEQ ID NO:2), or VTVLALGALAGVGVG (SEQ ID NO:3), in an amount sufficient to reduce or block B-cell lymphoma 10 (BCL10) expression or activity thereby reducing or blocking BCL10-mediated inflammation and/or treating a condition associated with BCL10-mediated inflammation in the mammalian subject.